Matsumoto Kazuya, Miyawaki Yoshia, Katsuyama Takayuki, Nakadoi Takato, Shidahara Kenta, Hirose Kei, Nawachi Shoichi, Asano Yosuke, Katayama Yu, Katsuyama Eri, Takano-Narazaki Mariko, Matsumoto Yoshinori, Mori Atsushi, Akagi Satoshi, Sada Ken-Ei, Wada Jun
Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Japan.
Department of Cardiovascular Medicine, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Japan.
Intern Med. 2024 Mar 1;63(5):671-676. doi: 10.2169/internalmedicine.1407-22. Epub 2023 Jul 19.
A 34-year-old woman with pulmonary arterial hypertension (PAH) was admitted to the hospital. She had been diagnosed with PAH three years earlier and treated with triple vasodilator therapy. She was positive for anti-U ribonucleoprotein antibodies but did not show any other symptoms associated with autoimmune diseases. Corticosteroid and cyclophosphamide therapy was administered, suspecting the involvement of immunological pathophysiology. After 3 weeks, the mean pulmonary artery pressure decreased from 50 to 38 mmHg without any change in the vasodilators. Immunosuppressive therapy was effective in this patient with PAH with an anti-U ribonucleoprotein-antibody-positive response and might be an option for patients with these specific features.
一名34岁的肺动脉高压(PAH)女性患者入院。她三年前被诊断为PAH,并接受了三联血管扩张剂治疗。她的抗U核糖核蛋白抗体呈阳性,但未表现出任何与自身免疫性疾病相关的其他症状。怀疑存在免疫病理生理学参与,给予了皮质类固醇和环磷酰胺治疗。3周后,平均肺动脉压从50 mmHg降至38 mmHg,血管扩张剂未发生任何变化。免疫抑制治疗对这名抗U核糖核蛋白抗体呈阳性反应的PAH患者有效,可能是具有这些特定特征患者的一种选择。